Neurological Recovery Following NOS-SACD

Nitrous oxide has become an increasingly popular recreational drug amongst young people, particularly at festivals, nightclubs and parties. Considering the drug is not illegal to possess, has low cost in the form of 'whippets' and can be easily purchased online, it has become the second most commonly used recreational drug amongst people aged 16-24 in the UK. However, nitrous oxide is known to irreversibly inactivate the functioning of vitamin B12, a vitamin required for the maintenance and proper functioning of nerves in the spinal cord. Neurological symptoms in this population have been reported in around 3.4% of nitrous oxide users, although the true incidence is expected to be higher as the cases being reported by UK hospitals continues to rise.

Patients may present with adverse neurological symptoms like tingling, weakness, coordination and mobility problems. Currently, studies reviewing the functional recovery of these patients have been limited by a retrospective study design, short follow up duration and being limited to small cohort sizes. This is in part linked to patient non-compliance and non-attendance at follow-up appointments. The investigators will therefore prospectively recruit all patients presenting with these symptoms and continue to collect data relating to their neurological recovery for 12 months. Data collection will be remote to ensure it is of low burden to the participants. This will allow the investigating team and others to fully appraise the severity of these toxic neuropathies and understand how best to manage their follow up.

This study will take place in selected participating hospitals, including their acute neurology units and emergency departments. Participants presenting to their GP will be referred per standard clinical care with the acute neurology units for study inclusion review. Ideally in all cases the investigating team would prefer for participants to be in hospitals (either directly through A\&E or being referred by their GP to the acute neurology service) at the time of study inclusion and for the baseline visit to ensure standard clinical care data can be collected (including MRI, bloods and treatment information including how many Vitamin B12 injections are given at admission and throughout their recovery). Care will be taken over by the neurology team where possible and standard clinical practice for participants with NOS induced neurological damage will be managed and treated as per their own local guidelines. Patients identified to the research team with consultant confirmed NOS-induced neuropathy but have left hospital can still be considered for the study but oral consent will be asked of these participants.

Baseline visit: participants who remain in hospital at the time of study invite will have their concomitant medications, comorbidities and a neurological assessment reviewed in person, blood and MRI results will also be collected from the routine tests that have been performed whilst in hospital. Participants not in the hospital at this point will have this information assessed where possible via the telephone or obtained from their medical records. Individuals without blood or MRI data will not be excluded from the study providing they meet the inclusion criteria.

At the point of consent (written or verbal), recruited participants details (NHS number, name and mobile number) will be securely shared with the coordinating Nottingham University Hospitals NHS Trust center. The Nottingham researcher will then add new participants to the PsychoPy platform which is the University of Nottingham spinoff company that allows remote clinical trial assessments. Each time a participant is added, the platform will automatically generate follow up dates for when each of the subsequent visits are due (baseline visit, 1-month, 3- month, 6-month and 12-month). The Nottingham coordinating team will generate a specific link from this platform each time a participant visit is due, the link will then be sent via text messaging from the coordinating centre to the participants mobile phone. These links can be opened and the visits completed from anywhere provided the participant has internet connection. The content of the visits will include: demographic \[baseline visit only\], NOS quantification, basic finger tapping task, cognitive function tasks, health questionnaire assessing participants ability to perform simple daily activities, the overall neuropathy limitations scale and the average step count for the last 7-days.

The coordinating team will continue to monitor completed and outstanding visits for all participants and where uncompleted, will send out reminder text messages to the participants.

Our pragmatic approach to perform only remote follow ups was based on the already previously reported high DNA rate in this patient population. All patients will participate in a total of 5 remote visit assessments over the 12-month period.

Eligibility Criteria:
Inclusion Criteria:

* Any patient first presented with paraesthesia, weakness, ataxia or gait disturbance with a history of NOS use (age limit 16-30) as of 01/04/2023.
* Patients who can read and write in English, so that they can complete the questionnaires.
* Patients must have received a definitive consultant neurologist confirmed diagnosis of NOS-induced neurological damage. This is possible as all eligible patients will have been reviewed by the neurology team prior to study involvement.

Exclusion Criteria:

•Other causes of previous neuropathy or neurodegeneration indicated.